Common use of Provision of Compounds Clause in Contracts

Provision of Compounds. 8.4.1 Subject to Section 10.1.1, Merck will deliver the Merck Compound [*] to BioLineRx’s, or its designee’s, location as specified by BioLineRx (“Delivery” with respect to such Merck Compound). Title and risk of loss for the Merck Compound shall transfer from Merck to BioLineRx at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of Merck Compound shall be borne by [*]. BioLineRx will, or will cause its designee to: (i) take delivery of the Merck Compound supplied hereunder; (ii) perform the acceptance procedures allocated to it under the Clinical Quality Agreement; (iii) subsequently label and pack the Merck Compound (in accordance with Section 8.5), and promptly ship the Merck Compound to the Study sites for use in the Study, in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement; and (iv) provide, from time to time at the reasonable request of Merck, the following information: any applicable chain of custody forms, in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.

Provision of Compounds. 8.4.1 Subject to Section 10.1.1, 8.4.1. Merck will deliver the Merck Compound [*] DAP (INCOTERMS 2010) to BioLineRxCompany’s, or its designee’s, location as specified by BioLineRx Company (“Delivery” with respect to such Merck Compound). Title and risk of loss for the Merck Compound shall transfer from Merck to BioLineRx Company at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of Merck Compound shall be borne by [*]Company. BioLineRx Company will, or will cause its designee to: (ia) take delivery of the Merck Compound supplied hereunder; (iib) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (iiic) subsequently label and pack the Merck Compound (in accordance with Section 8.5), ; and promptly ship the Merck Compound to the Study sites for use in the Study, in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement; and (ivd) provide, from time to time at the reasonable request of Merck, the following information: any applicable chain of custody forms, in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.

Provision of Compounds. 8.4.1 Subject to Section 10.1.1, 8.4.1. Merck will deliver the Merck Compound [***] to BioLineRxFLX’s, or its designee’s, location as specified by BioLineRx FLX (“Delivery” with respect to such Merck Compound). Title and risk of loss for the Merck Compound shall transfer from Merck to BioLineRx FLX at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of Merck Compound shall be borne by [*]FLX. BioLineRx FLX will, or will cause its designee to: (ia) take delivery of the Merck Compound supplied hereunder; (iib) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (iiic) subsequently label and pack the Merck Compound (in accordance with Section 8.5), ; and promptly ship the Merck Compound to the Study sites for use in the Study, in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement; and (ivd) provide, from time to time at the reasonable request of Merck, the following informationinformation [***]: any applicable chain of custody forms, in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.

Provision of Compounds. 8.4.1 Subject to Section 10.1.1, 8.4.1. Merck will deliver the Merck Compound [*] DAP (INCOTERMS 2010) to BioLineRx’sAntigen Express’, or its designee’s, location as specified by BioLineRx Antigen Express (“Delivery” with respect to such Merck Compound). Title and risk of loss for the Merck Compound shall transfer from Merck to BioLineRx Antigen Express at Delivery. All costs associated with the subsequent transportation, warehousing and distribution of Merck Compound shall be borne by [*]Antigen Express. BioLineRx Antigen Express will, or will cause its designee to: (i) take delivery of the Merck Compound supplied hereunder; (ii) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (iii) subsequently label and pack the Merck Compound (in accordance with Section 8.5), and promptly ship the Merck Compound to the Study sites for use in the Study, in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement; and (iv) provide, from time to time at the reasonable request of Merck, the following information: any applicable chain of custody forms, in-transport temperature recorder(s), records and receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.